Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer

doi:10.1136/jcp.2007.050906

HOME

HELP

FEEDBACK

SUBSCRIPTIONS

ORIGINAL ARTICLES

Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer

K Wako¹^,2^,3^,4, T Kawasaki¹^,2^,3^,4, K Yamana¹^,2^,3^,4, K Suzuki¹^,2^,3^,4, S Jiang¹^,2^,3^,4, H Umezu¹^,2^,3^,4, T Nishiyama¹^,2^,3^,4, K Takahashi¹^,2^,3^,4, T Hamakubo¹^,2^,3^,4, T Kodama¹^,2^,3^,4, M Naito¹^,2^,3^,4

¹ Division of Urology, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
² Division of Cellular and Molecular Pathology, Department of Cellular Function, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
³ Perseus Proteomics Inc., Tokyo, Japan
⁴ Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Japan

Correspondence to:
Koichi Wako, MD, Division of Urology, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Asahimachi-dori 1-757, Chuou-ku, Niigata 951-8510, Japan; kwako{at}med.niigata-u.ac.jp

Aims: The association between the expression of androgen receptor(AR) or androgen-converting enzymes and malignant potentialin prostate cancer (PCa) was examined.

Methods: PCa specimens from 44 cases of stage II, 10 cases of stage III,four cases of stage IV and two recurrent cases were semi-quantitativelystudied with immunohistochemistry for AR and androgen-convertingenzymes.

Results: The expression scores for AR, 5 ${alpha}$ -reductase type 1 (SRD5A1), 5 ${alpha}$ -reductasetype 2 (SRD5A2), and aldo-keto reductase family 1 member C3(AKR1C3) in the metastatic lesion of stage IV or recurrent cancer(n = 6) were 284.2 (30.1), 300 (0.0), 279.2 (51) and 254.2 (74.9),respectively; these scores were significantly higher than therespective scores of 121.8 (82.1), 135.1 (59.7), 167.0 (66.4)and 150.5 (62.8) for stage II and III cancer (n = 54) (p<0.001,p<0.001, p = 0.002 and p = 0.018, respectively). The expressionscores for AR and SRD5A1 in stage II and III cancer with Gleasonscore 7 (n = 19) were 128.7 (72.3) and 150.5 (52.9); these weresignificantly higher than the scores of 78.8 (67.2) and 100.0(39.6), respectively, for cancers with a Gleason score of $<=$ 6(n = 20) (p = 0.032 and p = 0.002, respectively). The expressionscores for AR, SRD5A1 and AKR1C3 in stage II and III cancerwith primary Gleason pattern $>=$ 4 (n = 21) were 158.1 (84.3), 158.3(61.1) and 173.8 (64.8); these were significantly higher thanthe scores of 98.6 (72.8), 120.3 (54.7) and 135.6 (57.6), respectively,for cancers with primary Gleason pattern $<=$ 3 (n = 33) (p = 0.011,p = 0.026 and p = 0.034, respectively). Within Gleason score9 cancer, the expression scores for AR and SRD5A1 in the primarylesion of stage IV (n = 3) were 276.7 (5.8) and 283.3 (28.9);these scores were significantly higher than the scores of 182.1(86.0) and 140.0 (56.6), respectively, for stage II and IIIcancer (n = 7) (p = 0.027 and p = 0.001, respectively).

Conclusions: Both AR and androgen-converting enzymes were upregulated inhigh-grade or advanced PCa.